In parallel, given the role of EDC4 in HR repair and the hypersensitivity of EDC4-depleted cell lines to PARP inhibition (Fig. 4f), our results suggest a therapeutic option for the treatment of EDC4-mutated breast cancers by synthetic lethality. Here, EDC4 is linked to breast carcinoma.